Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDC*lung01 cancer vaccine with or without anti-PD-1 in NSCLC
2024-517429-24-00Phase 2Completed
- Sponsor
- PDC*line Pharma
- Start
- Oct 2024
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
Phase 2, open-label trial of PDC*lung01 in non-small cell lung cancer (NSCLC) (4 arms), sponsored by PDC*line Pharma. Primary endpoint: Dose-limiting toxicities related to PDC*lung01. Started Oct 2024; status: completed.
02
Drugs
PDC*lung01
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-517429-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517429-24-00.